Tenshi Kaizen Private (Tenshi) on Bengaluru (India) and DolCas Biotech (DolCas) have formed DolCas-Tenshi Bioceuticals (DBT). The joint venture focuses on the research, development, and commercialisation of novel nutraceutical lines for key global markets, including the US, Canada, Europe, and Japan.
The two partners have equal interest and headquarters will be based in New Jersey.
DBT will allow the new company to create unique positioning for its products in the global nutraceuticals, functional food and beverage markets. It brings together the diverse capabilities of the two established partners, both with many years of experience in building and scaling innovative businesses.
Tenshi brings proprietary technologies in developing and manufacturing highly bioavailable nutraceutical products, and DolCas, with strong front-end capabilities, will spearhead the commercialization and go-to-market efforts.
DolCas has a proven, 10-year track record in establishing and marketing for two leading nutraceutical brands in the pain management and general well-being categories.
“Tenshi is delighted to partner with DolCas to build a significant branded dietary supplement business for the global markets,” said Venkat Iyer, Co-Founder of Tenshi.
“We strongly believe that DolCas’ legacy and reputation of bringing to market science-led dietary supplements offers the perfect complement to Tenshi’s development platform for its novel ingredients.”
According to industry reports, the global nutraceutical market is projected to reach $578 billion by 2025, driven predominantly by growing consumer awareness of the value of nutraceuticals in conjunction with the steady innovation of high-performance natural ingredients.
“With DolCas’ exemplary go-to-market abilities, the synergies of the two partners will accelerate the development of, and accessibility to, affordable, high quality nutraceuticals,” noted Iyer.
Iyer said the company is on course with the launch of its first two products at VitaFoods 2019 in May.
